The on-screen besties still have a fun dynamic ...

Lamont Bentley won over audiences as lovable, goofy next-door-neighbor Hakeem Campbell on Moesha. Toward the end of the ...

BRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted ...

Tony Dokoupil was called into work on a Saturday – two days before his official start, no less – but his reaction to the emergency launch of “CBS Evening News” was hardly a scene from “Office Space.” ...

Back in April 2024, I assigned Day One Biopharmaceuticals, Inc. (DAWN) stock a "Hold" rating in a note for the Seeking Alpha, covering the news that its lead asset tovorafenib had been awarded an ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Matthew Guay More than almost any other category, journaling software is about ...

Before she was a VC, Masha Bucher worked in PR and marketing — an experience that has shaped the way she runs Day One Ventures. After years of working in communications — including executive roles ...

I went skiing over Thanksgiving break for the first time this season. My goals for day one on the slopes were the same as they are every ski season: shock my ligaments and muscles into ski shape, make ...

Last year, when Michigan marched into Ohio Stadium and upset the Buckeyes, the Wolverines planted their flag at the 50-yard line following the game. Chaos ensued, punches were thrown and pepper spray ...

Canary Capital’s XRPC, the first U.S. spot exchange-traded fund (ETF) tied to payments-focused token XRP, marked an impressive debut Thursday with $58 million in trading volume — the highest for any ...

(RTTNews) - Mersana Therapeutics, Inc. (MRSN), a biopharmaceutical company, Thursday, announced that it has entered a definitive agreement to be acquired by Day One Biopharmaceuticals through a tender ...

Day One Biopharmaceuticals (DAWN) has signed a definitive merger agreement to acquire clinical-stage biopharmaceutical company Mersana Therapeutics (MRSN) in a deal value of up to around $285 million.